003) becomes the first dengue vaccine to be approved in India, marking a new era in dengue prevention
India has approved QDENGA, the country's first dengue vaccine, for individuals aged 4 to 60. The vaccine, developed by Takeda, is designed to protect against all four dengue serotypes and does not require pre-vaccination testing.
Why it matters
As India accounts for a significant portion of the global dengue burden, this approval represents a major advancement in public health and disease prevention.
The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades
QDENGA is now approved in 43 countries, including India, with more than 32 million doses distributed globally through public and private programs to date
Designed to protect against all four dengue virus serotypes, QDENGA can be used regardless of previous dengue exposure and without pre-vaccination testing
QDENGA is the most extensively studied dengue vaccine, with long-term data demonstrating sustained protection against dengue disease and dengue-related hospitalization
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in